We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Lab Information Systems Sector Reaches 1 Billion

By LabMedica International staff writers
Posted on 30 Dec 1899
Print article
The global laboratory information systems (LIS) sector reached USD 1 billion in 2015, in part due to the expected rebound of independent labs, according to a new healthcare market report on LIS.

The new report, “World Market for Laboratory Information Systems” by Kalorama Information (New York, NY, USA), focuses on the market for LIS (also known as LIMS – laboratory information management systems) in clinical diagnostic healthcare and pharmaceutical drug discovery laboratories, although other drug research & development labs are included.

After seeing business contract by nearly 5% over the past 5 years, independent labs are projected by Kalorama to realize new growth from expected increases from previously uninsured patients.

One of the main motivators for harnessing automation in laboratories involves increasing productivity by minimizing non-value-added steps, including such processes as sorting tubes, decapping, centrifugation, loading analyzers, and prepping & sorting materials for storage. Non-value-added steps usually can be addressed by automated systems. Many LIS offer modular-based systems with customizable functionality, scalability, and a high level of adaptable connectivity for access to EMRs.

Labs “anticipate much from their LIS, including an ability to connect virtually all lab instrumentation, perform automated data collection, and track workflow,” said Bruce Carlson, publisher of Kalorama Information, adding that installation of a LIS has “potential to increase a laboratory's productivity in the range of 40%-50% over time.”

Kalorama thinks there is a need for LIS in drug discovery and early-stage development to provide global access and enterprise visibility for cross-functional groups to leverage work already done and increase operating efficiency. Seamless enterprise-wide integration is a necessity as it makes key knowledge originating in the laboratory available to management in real-time. Integrating instrumentation and laboratories at different locations facilitates better data correlation and collaboration, end-to-end report generation, and more-secure data exchanges. Many believe that the LIS will become a central system for integrating all the data as the system is often the data management work horse, as well as a component of broader integration efforts.

Kalorama’s report provides full market coverage, including key facts about diagnostic labs; growth (1997–2014, and estimated 2015); world LIS market (2015–2020) for clinical, NGS, and drug discovery labs; major pharmaceutical companies, number of potential lab sites for LIS (2015); selected vendors; sites operating LIS; recent key vendor mergers & acquisitions; and more.

This report generally forecasts future growth to 2020. Market segments covered include North American, European, Brazilian, Chinese, and Japanese markets, as well as segments for LIS software, hardware, and implementation services.

Related Links:

Kalorama Information
World Market for Laboratory Information Systems, report


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more